Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) was the recipient of a significant increase in short interest during the month of September. As of September 30th, there was short interest totalling 444,600 shares, an increase of 35.8% from the September 15th total of 327,500 shares. Approximately 9.0% of the shares of the stock are sold short. Based on an average daily volume of 64,600 shares, the days-to-cover ratio is currently 6.9 days.

Separately, Zacks Investment Research cut Bellicum Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 11th.

BLCM stock opened at $6.87 on Friday. The business has a fifty day moving average of $6.34 and a two-hundred day moving average of $6.76. The stock has a market cap of $34.76 million, a price-to-earnings ratio of -0.34 and a beta of 1.87. Bellicum Pharmaceuticals has a 52-week low of $3.32 and a 52-week high of $27.90.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($2.47) earnings per share (EPS) for the quarter. As a group, analysts predict that Bellicum Pharmaceuticals will post -8.03 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of the business. UBS Group AG increased its stake in Bellicum Pharmaceuticals by 25.3% during the second quarter. UBS Group AG now owns 10,369 shares of the biopharmaceutical company’s stock worth $77,000 after acquiring an additional 2,094 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Bellicum Pharmaceuticals by 58.1% in the first quarter. Tower Research Capital LLC TRC now owns 12,917 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 4,745 shares in the last quarter. Sabby Management LLC acquired a new stake in shares of Bellicum Pharmaceuticals in the first quarter valued at $89,000. Bridgeway Capital Management Inc. acquired a new stake in shares of Bellicum Pharmaceuticals in the second quarter valued at $217,000. Finally, Principal Financial Group Inc. acquired a new stake in shares of Bellicum Pharmaceuticals in the second quarter valued at $396,000. 19.43% of the stock is owned by institutional investors.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen.

Featured Story: What is the price-to-earnings growth (PEG) ratio?

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.